GALECTIN THERAPEUTICS INC (GALT) Financial Statements
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GALTGALECTIN THERAPEUTICS INCFollow GALT — free
—
Price chart with a free account
- Market cap
- 321.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 16 Nov, in 23 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | 3.6 | 4.5 | 5.7 | 8.4 | 13.1 | 15.3 | 11.7 | 6.5 | 7.5 | 18.0 | 23.8 | 31.7 | 32.1 | 36.6 | 14.3 | 8.9 | |
| Operating income | -10.4 | -9.9 | -12.1 | -15.4 | -20.1 | -21.5 | -16.2 | -13.6 | -13.4 | -23.4 | -30.2 | -38.4 | -38.1 | -42.4 | -20.1 | -15.6 | |
| Pre-tax income | -10.9 | -9.7 | -12.1 | -15.8 | -20.0 | -21.4 | -16.2 | -13.9 | -13.3 | -23.5 | -30.5 | -38.8 | -41.1 | -47.0 | -30.8 | -27.8 | |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | — | |
| Net income | -10.9 | -9.7 | -12.1 | -15.8 | -20.0 | -21.4 | -16.2 | -13.9 | -13.3 | -23.5 | -30.5 | -38.8 | -41.1 | -47.0 | -30.8 | -27.8 | |
| Diluted EPS ($) | -1.06 | -0.72 | -1.30 | -0.78 | -0.88 | -0.76 | -0.49 | -0.38 | -0.39 | -0.41 | -0.52 | -0.65 | -0.74 | -0.76 | -0.48 | -0.43 | |
| Diluted shares (mn) | — | — | — | — | — | — | — | — | — | — | 58.5 | 59.4 | 60.2 | 62.3 | 63.9 | — |
USD millions · SEC XBRL
GALECTIN THERAPEUTICS INC — questions
- What is GALECTIN THERAPEUTICS INC's net income?
- -$27.8M over the twelve months to 2026-06-30.
- What are GALECTIN THERAPEUTICS INC's diluted earnings per share?
- $-0.43 over the twelve months to 2026-06-30.
Every figure on this page comes from GALECTIN THERAPEUTICS INC's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.